This book talks about conspiracy-a conspiracy that most of us don't even know exists. If you really want to know what the pharmaceutical industry is up to, you must read this book.

She Had Made the Company Millions Yet They Cut Her Loose

"I went to school and have my college degree. I married and had children. I had a successful career for 18 years-top sales with award winning trips for seven of those years. I have saved for my retirement. I have savings accounts for my children to go to college. I pay my taxes and volunteer my time to many worthy causes like the Epilepsy foundation and the Alzheimer's Association. Yes, I own two nice cars, a big screen TV, and expensive suits and am an incorrigible shopaholic, but I'm not rich by any stretch of the imagination. I'd been blessed with a comfortable middle class life until one split second took it all away."

Kimberly Cheryl was living the American Dream until she was seriously injured in a car accident. Unexpectedly fired by the company she long served, she found herself without a job, without insurance, and without any means of paying off her obligations. She quickly moved from a position of observer and participant of the health care industry to being adversely affected by the same system.

In Escape from the Pharma Drug Cartel, Cheryl reveals how our health care system is broken, unjust, and inhumane. "Every other industrialized nation manages to provide almost all its citizens with guaranteed health insurance, while spending less on health care than we do," Cheryl writes. How is it possible that the United States-a leader in health care development and drug discovery-is not able to provide its citizens with medical care when countries like Australia and China do?

In Escape from the Pharma Drug Cartel, Kimberly Cheryl takes the reader on a shocking, revealing, and provocative tour of the pharmaceutical industry of America as only an insider can.

Public concerns about the regulation of the pharmaceutical industry have intensified in recent years. Paradoxically, these concerns center on the over-consumption of medicines of dubious benefit in Western societies and lack of access to essential medicines in the Global South.

By demonstrating how the analysis of pharmaceutical drug regulation can provide rich insights into the operation of power and politics in contemporary society, the contributors challenge the prevailing construction of drug regulation as a sphere of “policy without politics” and suggest alternative ways of regulating medicines.

Just two of the central questions that are explored in this book include: what are the implications for health that arise from the existing systems of pharmaceutical drug regulation?; what do the existing systems of drug regulation reveal about the power of transnational pharmaceutical corporations to shape regulatory and other policies?

The importance attached to placing the Irish regulatory system in its international context is reflected in the inclusion of chapters that consider regulatory trends in Australia, Canada and Britain, and chapters that address the implications of World Trade Organisation and EU regulatory policies.

This econometric study covers the outlook for ophthalmic pharmaceutical drugs in Africa & the Middle East. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-a-vis others. Using econometric models which project fundamental economic dynamics within each country and across countries, latent demand estimates are created. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved.

This study does not report actual sales data (which are simply unavailable, in a comparable or consistent manner in virtually all of the countries in Africa & the Middle East). This study gives, however, my estimates for the latent demand, or the P.I.E. for ophthalmic pharmaceutical drugs in Africa & the Middle East. It also shows how the P.I.E. is divided across the national markets of Africa & the Middle East. For each country, I also show my estimates of how the P.I.E. grows over time (positive or negative growth). In order to make these estimates, a multi-stage methodology was employed that is often taught in courses on international strategic planning at graduate schools of business.

This econometric study covers the outlook for ophthalmic pharmaceutical drugs in Asia. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-a-vis others. Using econometric models which project fundamental economic dynamics within each country and across countries, latent demand estimates are created. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved.

This study does not report actual sales data (which are simply unavailable, in a comparable or consistent manner in virtually all of the countries in Asia). This study gives, however, my estimates for the latent demand, or the P.I.E. for ophthalmic pharmaceutical drugs in Asia. It also shows how the P.I.E. is divided across the national markets of Asia. For each country, I also show my estimates of how the P.I.E. grows over time (positive or negative growth). In order to make these estimates, a multi-stage methodology was employed that is often taught in courses on international strategic planning at graduate schools of business.

This econometric study covers the outlook for ophthalmic pharmaceutical drugs in Europe. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-a-vis others. Using econometric models which project fundamental economic dynamics within each country and across countries, latent demand estimates are created. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved.

This study does not report actual sales data (which are simply unavailable, in a comparable or consistent manner in virtually all of the countries in Europe). This study gives, however, my estimates for the latent demand, or the P.I.E. for ophthalmic pharmaceutical drugs in Europe. It also shows how the P.I.E. is divided across the national markets of Europe. For each country, I also show my estimates of how the P.I.E. grows over time (positive or negative growth). In order to make these estimates, a multi-stage methodology was employed that is often taught in courses on international strategic planning at graduate schools of business.

This econometric study covers the latent demand outlook for ophthalmic pharmaceutical drugs across the regions of Greater China, including provinces, autonomous regions (Guangxi, Nei Mongol, Ningxia, Xinjiang, Xizang - Tibet), municipalities (Beijing, Chongqing, Shanghai, and Tianjin), special administrative regions (Hong Kong and Macau), and Taiwan (all hereafter referred to as "regions"). Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across some 1,100 cities in Greater China. For each major city in question, the percent share the city is of the region and of Greater China is reported. Each major city is defined as an area of "economic population", as opposed to the demographic population within a legal geographic boundary. For many cities, the economic population is much larger that the population within the city limits; this is especially true for the cities of the Western regions. For the coastal regions, cities which are close to other major cities or which represent, by themselves, a high percent of the regional population, actual city-level population is closer to the economic population (e.g. in Beijing). Based on this "economic" definition of population, comparative benchmarks allow the reader to quickly gauge a city's marketing and distribution value vis-a-vis others. This exercise is quite useful for persons setting up distribution centers or sales force strategies. Using econometric models which project fundamental economic dynamics within each region and city of influence, latent demand estimates are created for ophthalmic pharmaceutical drugs. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view,

This econometric study covers the latent demand outlook for ophthalmic pharmaceutical drugs across the states, union territories and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 5,000 cities in India. For each city in question, the percent share the city is of it's state or union territory and of India as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a city vis-a-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state or union territory and city, latent demand estimates are created for ophthalmic pharmaceutical drugs. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved.

This study does not report actual sales data (which are simply unavailable, in a comparable or consistent manner in virtually all of the cities in India). This study gives, however, my estimates for the latent demand, or the P.I.E., for ophthalmic pharmaceutical drugs in India. It also shows how the P.I.E. is divided and concentrated across the cities and regional markets of India. For each state or union territory, I also show my estimates of how the P.I.E. grows over time. In order to make these estimates, a multi-stage methodology was employed that is often taught in courses on strategic planning at graduate schools of business.